Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13868456 | 1.00 | HCRTR2 (0.33) | HCRTR2TSHRALDH1A1RECQLGAA | |
| SCHEMBL3905546 | 0.92 | MAPT (0.32) | HCRTR2TSHRMAPTHCRTR1 | |
| SCHEMBL13868458 | 0.92 | MAPT (0.32) | HCRTR2TSHRMAPTHCRTR1 | |
| SCHEMBL13868449 | 0.90 | MAPT (0.33) | HCRTR2ALDH1A1GAAMAPTL3MBTL1 | |
| SCHEMBL3902845 | 0.90 | MAPT (0.33) | HCRTR2ALDH1A1GAAMAPTL3MBTL1 | |
| SCHEMBL13868453 | 0.87 | — | — | |
| SCHEMBL3906547 | 0.87 | — | — | |
| SCHEMBL3905847 | 0.87 | SMN1; SMN2 (0.33) | TSHRALDH1A1MAPTL3MBTL1 | |
| SCHEMBL13868386 | 0.78 | MEN1 (0.37) | ALDH1A1RECQLGAAMAPTKDM4E | |
| SCHEMBL3903176 | 0.69 | GRM2 (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060024330-A1 | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2006-02-02 | — | — | US | claimed |
| US-7517532-B2 | Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20060024330-A1 | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060024330-A1 | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors | DHPS, DUT, CDKN1A | HCRTR2 4149/4885TSHR 4242/4885ALDH1A1 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.